Ampersand Announces Successful Exit of CutisPharma

PRESS RELEASE


Ampersand Announces Successful Exit of CutisPharma


Wellesley, Mass., March 26, 2018. Ampersand Capital Partners announced today that portfolio company CutisPharma has been acquired by NovaQuest Capital Management, LLC. In December 2014, Ampersand completed a growth equity investment into CutisPharma, which at the time was a founder-run company with no institutional investors. Ampersand’s goal was to actively support management in the building of CutisPharma’s operational capabilities and the development FDA approved products. In January 2018, Cutis announced the approval of FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the treatment of lostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.

Eric Lev, Partner at Ampersand Capital noted, "CutisPharma has undergone an amazing transformation over the last three years; we're very pleased to have been a partner to CEO Neal Muni and his management team in building Cutis into a fully integrated specialty pharmaceutical company.”


About CutisPharma

CutisPharma, Inc., based in Wilmington, Mass., is a specialty pharmaceutical company that has been the industry leader for 20 years in providing innovative solutions to pharmacists. CutisPharma’s FIRST® Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. The Company’s first FDA-approved kit, FIRVANQ™, will improve patient access and aid pharmacists in conveniently delivering safe, affordable and easily verifiable, oral liquid formulations to patients. For more information, visit cutispharma.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Avista Pharma, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com.